Abiraterone
Commons · Question 50038 · Tabled 2 May 2025 · Department of Health and Social Care · Official record
Answered 12 May 2025
Question
Asked by Edward Morello
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 of April 2025 to Question 46588 on Abiraterone, what discussions she has had with NICE on its engagement with health authorities on the (a) appraisal and (b) use of abi
Answer
Answered by Karin Smyth, 12 May 2025
The Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and C...